Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019 | ||
By: PR Newswire Association LLC. - 25 Apr 2019 | Back to overview list |
|
HOUSTON and VANCOUVER, April 25, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre in Toronto, Ontario, Canada. Dr. Parkinson will provide a corporate overview of the Company's business and will be available for one-on-one meetings from April 29 – May 1, 2019. ESSA's Chief Financial Officer, David S. Wood, and Chief Operating Officer, Peter Virsik, will also be in attendance The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/bloomburton4/epi/. The webcast replay will remain available on the Company's website (www.essapharma.com) for 90 days following the live presentation. Presentation Details : Event: Bloom Burton & Co. Healthcare Investor Conference 2019 About ESSA Pharma Inc. ESSA proprietary compounds, otherwise known as aniten compounds, bind to the N-terminal domain of the androgen receptor ("AR"). The company is currently conducting studies on a small number of next generation compounds with higher potency and metabolic stability, longer half-life and superior pharmaceutical properties. About the Conference: About Bloom Burton & Co.: About Prostate Cancer Forward-Looking Statement Disclaimer Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 13, 2018 under the heading "Risk Factors", a copy of which is available on ESSA's profile on the SEDAR website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View original content:http://www.prnewswire.com/news-releases/essa-pharma-to-attend-bloom-burton--co-healthcare-investor-conference-2019-300837935.html SOURCE ESSA Pharma Inc |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |